New Novartis Drug Can Help Ease Heavy Socio-economic Burden of Heart Failure

New Novartis Drug Can Help Ease Heavy Socio-economic Burden of Heart Failure

 

With its proven efficacy in improving survival and reducing hospitalizations among patients with heart failure with reduced ejection fraction, Sacubitril-Valsartan can improve treatment outcomes and patients’ quality of life thereby easing the disease burden on families, society and the country.

• Every year, heart failure costs the world economy almost five trillion pesos, with hospitalizations comprising 60% to 70% of direct treatment costs. The latest National Nutrition and Health Survey show that many Filipinos are hypertensive, obese, smokers, and have high cholesterol and diabetes—all risk factors for heart failure.

Quezon City, April 21, 2016 – With its proven efficacy in improving survival and reducing hospitalizations among patients with heart failure with reduced ejection fraction, Sacubitril-Valsartan can improve treatment outcomes and patients’ quality of life thereby easing the disease burden on families, society and the country.

Heart failure is a serious life-threatening condition in which the heart weakens and cannot pump enough blood to fully meet the oxygen demand of the body. Over time, if not treated properly, heart failure leads to severe fatigue; breathlessness; damage particularly to the heart, kidneys and liver; and ultimately death.

Developed by research-based Swiss healthcare company Novartis, Sacubitril-Valsartan is a twice-daily oral pill that provides a novel strategy for treating heart failure. It amplifies the natural defense response of the heart, while simultaneously suppressing the harmful effects of the body’s hormone system, ultimately leading to reduced strain on the cardiovascular system.

“Every year, heart failure costs the world economy almost five trillion pesos, with hospitalizations comprising 60% to 70% of direct treatment costs. The latest National Nutrition and Health Survey show that many Filipinos are hypertensive, obese and smokers, and have high cholesterol and diabetes—all risk factors for heart failure. Sacubitril-Valsartan can help ease the heavy socio-economic burden imposed by heart failure on patients and their family as well as the country’s economy and healthcare system,” said Dr. John Anonuevo, Clinical Associate Professor, University of the Philippines-Philippine General Hospital.

Dr. Anonuevo spoke during the Philippine launch of sacubitril/valsartan. The launch was held in conjunction with a scientific meeting organized by Novartis Healthcare Philippines on April 21, 2016 at the Crowne Plaza Manila Galleria in Ortigas Center, Quezon City. Entitled “Advancing Care, Inspiring Change, Taking Actions”, the scientific meeting was attended by local cardiologists, internists and other medical specialists.

Heavy disease burden
Heart failure is a significant and growing public health concern. Despite currently available medicines, heart failure continues to cause frequent hospitalization, poor quality of life, disability, loss of productivity and death. Heart failure is the most common cause of hospitalization in people aged over 65. One in 25 patients do not survive their first hospitalization with heart failure as the primary diagnosis. One in 10 patients die within 30 days following hospitalization. Up to 1 in 3 patients die within one year following hospitalization. Half of all patients die within five years of diagnosis. In patients with heart failure with reduced ejection fraction, almost half (45%) of cardiovascular deaths and 36% of all-cause deaths are sudden.

“Heart failure takes a heavy toll on patients and their family, and repeated hospitalizations just makes matters worse. The landmark PARADIGM-HF Trial has shown that Sacubitril-Valsartan improves survival and reduces the frequency of hospitalization among patients with heart failure with reduced ejection fraction,” said Dr. Nikolaos Tripodis, President & Managing Director, Novartis Healthcare Philippines.

Sacubitril-Valsartan is a prescription medication and should be taken only upon the advice of a physician. It is available in all leading drugstores and pharmacies nationwide.

PHOTO CAPTION: (DCS_0516)
“Heart failure takes a heavy toll on patients and their family, and repeated hospitalizations just makes matters worse. The landmark PARADIGM-HF Trial has shown that Sacubitril-Valsartan improves survival and reduces the frequency of hospitalization among patients with heart failure with reduced ejection fraction,” said Dr. Nikolaos Tripodis, President & Managing Director, Novartis Healthcare Philippines. Dr. Tripodis spoke during the Philippine launch of Sacubitril-Valsartan on April 21, 2016 at the Crowne Plaza Manila Galleria, which was attended by local cardiologists, internists and other medical specialists.

References:

1. LCZ696 Fast Facts, on file
2. John J.V. McMurray, M.D., Milton Packer, M.D., Akshay S. Desai, M.D., M.P.H., Jianjian Gong, Ph.D., Martin P. Lefkowitz, M.D., Adel R. Rizkala, Pharm.D., Jean L. Rouleau, M.D., Victor C. Shi, M.D., Scott D. Solomon, M.D., Karl Swedberg, M.D., Ph.D., and Michael R. Zile, M.D., for the PARADIGM-HF Investigators and Committees. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med 2014; 371:993-1004September 11, 2014DOI: 10.1056/NEJMoa1409077

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 119,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit http://www.novartis.com

Leave a Reply

Your email address will not be published. Required fields are marked *

*